Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 1997

View Archived Issues

Calcimimetic agent shown active in preclinical models of hyperparathyroidism

NeuroSearch: 1997 half-year highlights

rhBMP-2 promotes periodontal wound healing in rodent model

Andrx's extended-release diltiazem receives tentative approval

Phase I results with HGP-30 AIDS vaccine reported

Takeda and McNeil sign OTC collaboration

NCI sponsors trials of new treatment for MDR in multiple myeloma

Scotia signs licensing agreements for Foscan

Phase I results reported for MiKasome

Safer glucocorticoids for inflammatory/allergic disorders

Tachykinin antagonists prepared at Janssen

Eel calcitonin nasal spray evaluated in phase I

Novel leukotriene antagonists from Menarini

Receptagen, Scitech Genetics sign letter of intent to merge

Taisho/Nihon Nohyaku evaluate thiazole derivatives as antipsychotics

Carbachol analogue selective for m1 receptors in vivo

TP-9201 as adjunct to thrombolysis in stroke

Highly selective 5-HT1D agonists described by MS&D

Eisai presents novel potential antipsychotic agent

Famvir approved by FDA for new indication

Vaxar: first launch for new fluoroquinolone

Generic naproxen introduced in U.S.

Pramipexole monotherapy treats parkinsonian symptoms for up to two years

First approvals for Lovenox/Clexane in unstable angina/MI

Vaccine for colorectal cancer enters phase I/II

Additional PLAs filed for INVICORP

Levormeloxifene preclinical and clinical data presented

FDA panel recommends approval of Paxene

NCI to fund clinical trials of Pharmacyclics' Gd-Tex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...